REGiMMUNE initiates patient enrollment in Phase II trial to treat Graft versus host disease
The randomized, open-label, multicenter Phase II trial is being carried out in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). It is being conducted in six US cancer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.